title: Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma.
abstract: Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is the first targeted therapy to improve survival in a molecularly unselected population, and represents a valuable new treatment option. This review describes the current treatment landscape for advanced disease, evaluates existing and ongoing research into ramucirumab, and discusses its current and potential future therapeutic role.
authors.affiliation: Department of Gastrointestinal Cancer Research, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
authors.forename: Michael
authors.initials: M
authors.lastname: Davidson
authors.affiliation: Department of Gastrointestinal Cancer Research, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
authors.forename: Elizabeth C
authors.initials: EC
authors.lastname: Smyth
authors.affiliation: Department of Gastrointestinal Cancer Research, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
authors.forename: David
authors.initials: D
authors.lastname: Cunningham
keywords: advanced gastric cancer; angiogenesis inhibitors; paclitaxel; ramucirumab